DNA immunization against experimental genital herpes simplex virus infection

Nigel Bourne, Lawrence R. Stanberry, David I. Bernstein, Denise Lew

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

A nucleic acid vaccine, expressing the gene encoding herpes simplex virus (HSV) type 2 glycoprotein D (gD2) under control of the cytomegalovirus immediate-early gene promoter, was used to immunize guinea pigs against genital HSV-2 infection. The vaccine elicited humoral immune responses comparable to those seen after HSV-2 infection. Immunized animals exhibited protection from primary genital HSV-2 disease with little or no development of vesicular skin lesions and significantly reduced HSV-2 replication in the genital tract. After recovery from primary infection, immunized guinea pigs experienced significantly fewer recurrences and had significantly less HSV-2 genomic DNA detected in the sacral dorsal root ganglia compared with control animals. Thus, immunization reduced the burden of latent infection resulting from intravaginal HSV-2 challenge, and a nucleic acid vaccine expressing the HSV-2 gD2 antigen protected guinea pigs against genital herpes, limiting primary infection and reducing the magnitude of latent infection and the frequency of recurrent disease.

Original languageEnglish (US)
Pages (from-to)800-807
Number of pages8
JournalJournal of Infectious Diseases
Volume173
Issue number4
StatePublished - 1996
Externally publishedYes

Fingerprint

Herpes Genitalis
Human Herpesvirus 2
Immunization
DNA
Virus Diseases
Guinea Pigs
DNA Vaccines
Infection
Immediate-Early Genes
Spinal Ganglia
Humoral Immunity
Virus Replication
Cytomegalovirus
Vaccines
Antigens
Recurrence
Skin

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

DNA immunization against experimental genital herpes simplex virus infection. / Bourne, Nigel; Stanberry, Lawrence R.; Bernstein, David I.; Lew, Denise.

In: Journal of Infectious Diseases, Vol. 173, No. 4, 1996, p. 800-807.

Research output: Contribution to journalArticle

Bourne, N, Stanberry, LR, Bernstein, DI & Lew, D 1996, 'DNA immunization against experimental genital herpes simplex virus infection', Journal of Infectious Diseases, vol. 173, no. 4, pp. 800-807.
Bourne, Nigel ; Stanberry, Lawrence R. ; Bernstein, David I. ; Lew, Denise. / DNA immunization against experimental genital herpes simplex virus infection. In: Journal of Infectious Diseases. 1996 ; Vol. 173, No. 4. pp. 800-807.
@article{73d15d8336604c6692a2a1b8d9b6debc,
title = "DNA immunization against experimental genital herpes simplex virus infection",
abstract = "A nucleic acid vaccine, expressing the gene encoding herpes simplex virus (HSV) type 2 glycoprotein D (gD2) under control of the cytomegalovirus immediate-early gene promoter, was used to immunize guinea pigs against genital HSV-2 infection. The vaccine elicited humoral immune responses comparable to those seen after HSV-2 infection. Immunized animals exhibited protection from primary genital HSV-2 disease with little or no development of vesicular skin lesions and significantly reduced HSV-2 replication in the genital tract. After recovery from primary infection, immunized guinea pigs experienced significantly fewer recurrences and had significantly less HSV-2 genomic DNA detected in the sacral dorsal root ganglia compared with control animals. Thus, immunization reduced the burden of latent infection resulting from intravaginal HSV-2 challenge, and a nucleic acid vaccine expressing the HSV-2 gD2 antigen protected guinea pigs against genital herpes, limiting primary infection and reducing the magnitude of latent infection and the frequency of recurrent disease.",
author = "Nigel Bourne and Stanberry, {Lawrence R.} and Bernstein, {David I.} and Denise Lew",
year = "1996",
language = "English (US)",
volume = "173",
pages = "800--807",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - DNA immunization against experimental genital herpes simplex virus infection

AU - Bourne, Nigel

AU - Stanberry, Lawrence R.

AU - Bernstein, David I.

AU - Lew, Denise

PY - 1996

Y1 - 1996

N2 - A nucleic acid vaccine, expressing the gene encoding herpes simplex virus (HSV) type 2 glycoprotein D (gD2) under control of the cytomegalovirus immediate-early gene promoter, was used to immunize guinea pigs against genital HSV-2 infection. The vaccine elicited humoral immune responses comparable to those seen after HSV-2 infection. Immunized animals exhibited protection from primary genital HSV-2 disease with little or no development of vesicular skin lesions and significantly reduced HSV-2 replication in the genital tract. After recovery from primary infection, immunized guinea pigs experienced significantly fewer recurrences and had significantly less HSV-2 genomic DNA detected in the sacral dorsal root ganglia compared with control animals. Thus, immunization reduced the burden of latent infection resulting from intravaginal HSV-2 challenge, and a nucleic acid vaccine expressing the HSV-2 gD2 antigen protected guinea pigs against genital herpes, limiting primary infection and reducing the magnitude of latent infection and the frequency of recurrent disease.

AB - A nucleic acid vaccine, expressing the gene encoding herpes simplex virus (HSV) type 2 glycoprotein D (gD2) under control of the cytomegalovirus immediate-early gene promoter, was used to immunize guinea pigs against genital HSV-2 infection. The vaccine elicited humoral immune responses comparable to those seen after HSV-2 infection. Immunized animals exhibited protection from primary genital HSV-2 disease with little or no development of vesicular skin lesions and significantly reduced HSV-2 replication in the genital tract. After recovery from primary infection, immunized guinea pigs experienced significantly fewer recurrences and had significantly less HSV-2 genomic DNA detected in the sacral dorsal root ganglia compared with control animals. Thus, immunization reduced the burden of latent infection resulting from intravaginal HSV-2 challenge, and a nucleic acid vaccine expressing the HSV-2 gD2 antigen protected guinea pigs against genital herpes, limiting primary infection and reducing the magnitude of latent infection and the frequency of recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=0029931269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029931269&partnerID=8YFLogxK

M3 - Article

C2 - 8603957

AN - SCOPUS:0029931269

VL - 173

SP - 800

EP - 807

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -